# NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

> **NCT00667082** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 22 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Melanoma
- Lymphoma
- Multiple Myeloma

## Interventions

- **DRUG:** NPI-0052 (marizomib) + vorinostat

## Key facts

- **NCT ID:** NCT00667082
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667082, "NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00667082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*